Alector (ALEC) Total Non-Current Liabilities (2018 - 2026)
Alector (ALEC) reported Total Non-Current Liabilities of $227.8 million for Q1 2026, down 27.07% year-over-year from $312.3 million in Q1 2025, and down 12.68% quarter-over-quarter from $260.9 million in Q4 2025.
Alector (ALEC) Total Non-Current Liabilities (2018 - 2026) Analysis & Trends
Alector (ALEC) has 9 years of Total Non-Current Liabilities data on file, last reported at $227.8 million in Q1 2026.
- Total Non-Current Liabilities for Q1 2026 came in at $227.8 million, down 27.07% year-over-year; the trailing twelve-month figure through Mar 2026 was $227.8 million (down 27.07% YoY), and the FY2025 annual result was $260.9 million, down 23.34% from the prior year.
- Total Non-Current Liabilities retreated to $227.8 million in Q1 2026 per ALEC's latest filing, from $260.9 million in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $686.8 million in Q1 2022 and troughed at $227.8 million in Q1 2026.
- A 5-year average of $440.4 million and a median of $455.2 million in 2024 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 223.37% in 2022, then tumbled 32.25% in 2025.
- A 5-year view of Total Non-Current Liabilities shows it stood at $572.4 million in 2022, then dropped by 15.05% to $486.3 million in 2023, then plunged by 30.03% to $340.3 million in 2024, then retreated by 23.34% to $260.9 million in 2025, then retreated by 12.68% to $227.8 million in 2026.
- Business Quant data shows ALEC's Total Non-Current Liabilities at $227.8 million in Q1 2026, $260.9 million in Q4 2025, and $276.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 42,980.09 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 11.03 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 95.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 644,700.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 5.87 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 64.76 Mn |
| 10 | Alector | 193.53 Mn | -12.98 Mn | - | 227.76 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 227.76 Mn |
| Dec 31, 2025 | 260.85 Mn |
| Sep 30, 2025 | 276.13 Mn |
| Jun 30, 2025 | 283.80 Mn |
| Mar 31, 2025 | 312.30 Mn |
| Dec 31, 2024 | 340.27 Mn |
| Sep 30, 2024 | 395.86 Mn |
| Jun 30, 2024 | 418.93 Mn |
| Mar 31, 2024 | 455.21 Mn |
| Dec 31, 2023 | 486.30 Mn |
| Sep 30, 2023 | 508.94 Mn |
| Jun 30, 2023 | 511.53 Mn |
| Mar 31, 2023 | 564.43 Mn |
| Dec 31, 2022 | 572.45 Mn |
| Sep 30, 2022 | 583.70 Mn |
| Jun 30, 2022 | 600.92 Mn |
| Mar 31, 2022 | 686.76 Mn |
| Dec 31, 2021 | 513.78 Mn |
| Sep 30, 2021 | 518.18 Mn |
| Jun 30, 2021 | 212.44 Mn |